BioNTech SE (FRA:22UA)
Germany · Delayed Price · Currency is EUR 84.80
-0.75 (-0.88%)
At close: Sep 18, 2026
BioNTech SE Revenue
BioNTech SE had revenue of 145.80M EUR in the quarter ending June 30, 2026, a decrease of -56.99%. This brings the company's revenue in the last twelve months to 2.78B, down -3.41% year-over-year. In the year 2025, BioNTech SE had annual revenue of 3.05B with 5.63% growth.
Revenue (ttm)
2.78B
Revenue Growth
-3.41%
P/S Ratio
7.94
Revenue / Employee
339.44K
Employees
7,807
Market Cap
21.04B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.05B | 162.80M | 5.63% |
| Dec 31, 2024 | 2.89B | -1.03B | -26.31% |
| Dec 31, 2023 | 3.92B | -13.39B | -77.33% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | 108.60M | -18.98M | -14.87% |
| Dec 31, 2018 | 127.58M | 65.98M | 107.11% |
| Dec 31, 2017 | 61.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.38B |
| Fresenius SE & Co. KGaA | 23.28B |
| Siemens Healthineers AG | 23.17B |
| Merck KGaA | 21.14B |
| Fresenius Medical Care AG | 19.43B |
| Sartorius Aktiengesellschaft | 3.58B |
| Fielmann Group AG | 2.46B |
| Carl Zeiss Meditec AG | 2.18B |
BioNTech SE News
- 3 days ago - Health Canada authorizes Pfizer, BioNTech’s Omicron XFG-adapted Covid-19 vaccine - TheFly
- 4 days ago - BioNTech price target raised to $140 from $132 at Berenberg - TheFly
- 6 days ago - BioNTech, OncoC4 announce first median overall survival data from PRESERVE-003 - TheFly
- 6 days ago - BioNTech says lung cancer drug candidate prolonged lives in trial - Reuters
- 6 days ago - BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients - GlobeNewsWire
- 12 days ago - BioNTech downgraded to Market Perform from Outperform at BMO Capital - TheFly
- 20 days ago - BioNTech price target lowered to $136 from $142 at Canaccord - TheFly
- 23 days ago - BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why - TipRanks